张琪

    [摘要] 目的 探討孟鲁司特钠联合布地奈德福莫特罗粉治疗咳嗽变异性哮喘的临床效果。方法? 选择2020年7月至2021年6月黑龙江省佳木斯市中心医院诊断治疗的咳嗽变异性哮喘患者60例进行回顾性分析，分为观察组与对照组各30例。观察组治疗采用孟鲁司特钠联合布地奈德福莫特罗，对照组治疗采用布地奈德福莫特罗。比较两组治疗1周、1个月咳嗽频率、程度评分，肺功能指标。结果? ①治疗1个月后两组的咳嗽频率评分与咳嗽程度评分均呈下降趋势，与治疗前比较，差异有统计学意义(P<0.05);治疗1周、治疗1个月，观察组咳嗽频率评分及咳嗽程度评分均显著低于对照组，差异有统计学意义(P<0.05)。②治疗1周与治疗1个月，观察组FEV1、PEF、FEV1/FVC均呈显著上升的趋势，与治疗前比较，差异有统计学意义(P<0.05);治疗1个月后，观察组FEV1、PEF、FEV1/FVC均显著高于对照组，差异有统计学意义(P<0.05)。结论? 孟鲁司特钠联合布地奈德福莫特罗用于咳嗽变异性哮喘的治疗可以有效控制症状，改善肺功能。

    [关键词] 孟鲁司特钠;布地奈德福莫特罗;咳嗽变异性哮喘;肺功能

    [中图分类号] R562.2+5? ? ? ? ? [文献标识码] B? ? ? ? ? [文章编号] 1673-9701(2022)11-0128-03

    [Abstract] Objective To investigate the clinical efficacy of montelukast sodium combined with budesonide and formoterol fumarate powder in the treatment of cough variant asthma. Methods The clinical data of 60 patients with cough variant asthma diagnosed and treated in the Central Hospital of Jiamusi City in Heilongjiang Province from July 2020 to June 2021 were retrospectively analyzed. The 60 patients were divided into 30 cases each in the observation group and the control group according to the treatment methods. The observation group was treated with montelukast sodium combined with budesonide and formoterol fumarate ......